PATENT CLAIM ANALYSIS

Application Number: 16059960
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "461000"]

Abstract:
Prodrugs of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.

Claim (Index 32):
A method of treating a disease or disorder in a subject in need thereof, wherein the method comprises administering to the subject a compound according to  claim 18 , said disease or disorder being selected from the group consisting of: solid cancers, hematological cancers, benign tumors, hyperproliferative diseases, inflammations, autoimmune diseases, graft or transplant rejections, delayed physiological function of grafts or transplants, neurodegenerative diseases and viral infections, such as from solid cancers and hematological cancers.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 96.0
- Lexical Diversity: 1.22581
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15124096', '13811015', '15578589', '13202875', '12668599']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8518505837296395
- 35 USC 102 Novelty (BERT): 0.6357377560980308
- Combined Prediction Score: 0.8302393009664786
- Mean Citation Score: 556.556944
- Max Citation Score: 727.63806
- Similarity Product: 523.8283829618382

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test